In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

Member Benefit

This content is only available year-round to ESC Professional Members, Fellows of the ESC, and Young Combined Members

Left trial appendage thrombosis in patients with severe aortic stenosis treated by transfemoral transcatheter aortic valve implantation

Session Poster Session 4

Speaker Norman Mangner

Event : ESC Congress 2019

  • Topic : valvular, myocardial, pericardial, pulmonary, congenital heart disease
  • Sub-topic : Intervention
  • Session type : Poster Session

Authors : N Mangner (Dresden,DE), G Stachel (Leipzig,DE), F Woitek (Dresden,DE), L Crusius (Leipzig,DE), S Haussig (Dresden,DE), P Kiefer (Leipzig,DE), S Leontyev (Leipzig,DE), F Schlotter (Leipzig,DE), A Spindler (Leipzig,DE), R Hoellriegel (Dresden,DE), J Hommel (Dresden,DE), M Borger (Leipzig,DE), H Thiele (Leipzig,DE), D Holzhey (Leipzig,DE), A Linke (Dresden,DE)

N. Mangner1 , G. Stachel2 , F. Woitek1 , L. Crusius2 , S. Haussig1 , P. Kiefer2 , S. Leontyev2 , F. Schlotter2 , A. Spindler2 , R. Hoellriegel1 , J. Hommel1 , M. Borger2 , H. Thiele2 , D. Holzhey2 , A. Linke1 , 1Heart Center Dresden - Technical University of Dresden - Dresden - Germany , 2University of Leipzig, Heart Center - Leipzig - Germany ,

Valvular Heart Disease: Intervention

European Heart Journal ( 2019 ) 40 ( Supplement ), 2300

Introduction: Data about the impact of left atrial appendage thrombosis (LAAT) on early safety and midterm mortality in patients undergoing transfemoral (TF) transcatheter aortic valve implantation (TAVI) are scarce.

Purpose: To investigate the incidence and predictors of LAAT as well as the outcome associated with this condition in a large cohort of patients treated by TF-TAVI.

Methods: Patients receiving TF-TAVI for native aortic valve stenosis or failed aortic bioprostheses were stratified according to the presence of LAAT diagnosed by transoesophageal echocardiography. Early safety at 30-days according to Valve Academic Research Consortium-2 (VARC-2) and 2-year all-cause mortality were the primary outcome measures.

Results: From 02/2006 to 06/2016, 2.527 patients (88.5%) out of 2.854 patients treated by TF-TAVI had an available transesophageal echocardiography (TEE) at baseline and formed the analysis cohort. LAAT was found in 7.6% of the whole cohort and in 16.6% in those patients with known pre-existing atrial fibrillation (AF cohort). Patients with LAAT appeared to be sicker compared to controls indicated by a higher STS-Score and burden of comorbidities. Neither VARC-2 defined early safety at 30-days nor the rate of stroke was different between LAAT and controls in both the whole (early safety: 24.2% vs. 29.2%, p=0.123; stroke: 4.7% vs. 5.9%, p=0.495) and AF cohort (early safety: 22.9% vs. 29.1%, p=0.072; stroke: 3.3% vs. 5.6%, p=0.142). Evaluating the whole cohort in a univariate analysis, the 2-year mortality was significantly higher in LAAT compared to controls (HR 1.41 [95% CI 1.07–1.86], p=0.014). However, a multivariate analysis of the whole cohort and a separate examination of the AF cohort revealed no association between LAAT and 2-year mortality.

Conclusion: LAAT was frequent in patients undergoing TF-TAVI, in particular in patients with a history of AF, but it was not associated with an increase in periprocedural complications. The fact that LAAT was no independent predictor of mortality indicates that it should be interpreted as a marker of an advanced disease stage rather than a prognostic factor.

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now
logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are